AdametNext

𝐀𝐭𝐲𝐩𝐢𝐜𝐚𝐥 𝐇𝐞𝐦𝐨𝐥𝐲𝐭𝐢𝐜 𝐔𝐫𝐞𝐦𝐢𝐜 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞 (𝐚𝐇𝐔𝐒): 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 Atypical HUS (aHUS) is a rare, life-threatening disorder driven by uncontrolled complement activation, leading to thrombotic microangiopathy (TMA), organ damage, and renal failure.   💊 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐀𝐥𝐠𝐨𝐫𝐢𝐭𝐡𝐦: ✔️ Complement inhibition remains the cornerstone of therapy, with Soliris (eculizumab) and Ultomiris (ravulizumab) by AstraZeneca as the primary approved treatments. ✔️ Supportive care includes plasma exchange, dialysis, and blood pressure management.   📊 𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 🔹 Next-generation complement inhibitors are expanding treatment options. 🔹Iptacopan (Fabhalta) by Novartis and Crovalimab (Piasky) by Roche—both recently approved for PNH—are in late-stage development for aHUS. 🔹 Ongoing trials explore extended dosing regimens, oral alternatives, and novel complement pathway targets. As new therapies reshape the treatment paradigm, how do you see the future of aHUS management evolving?   🏥 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Novartis, Roche, AstraZeneca   💡 Want to stay ahead of aHUS advancements? ✍ Reach out to us at [email protected] for more insights! Prepared by Amit Arya, PhD and Arpita Panigrahi Virendra Kumar AdametNext #RareDiseases #aHUS #ComplementInhibition #ClinicalResearch #Hematology #Nephrology #Adametnext

"Legacy is not just about what we leave behind; it’s about what we build for the future." NIPER MBA has always been more than just subjects and markets—it’s a journey of transformation, resilience, and camaraderie. It’s about shaping future leaders, igniting hidden potential, and fostering a spirit of innovation. And at the heart of this evolution lies a tradition that started with a simple yet powerful idea—81mg. Years ago, a group of passionate super seniors envisioned 81mg as a platform to prepare students for the corporate world—not just through academics but through holistic learning. What started as a minuscule initiative, executed by juniors and seniors together, has now evolved into Samprabhav, a grand-scale event that brings together industry leaders, experts, and aspiring professionals from across India. The passion that once sparked a legacy has now become an unstoppable movement. One person who has always championed this spirit is Virendra Kumar. His unwavering belief in the potential of NIPER MBA students, his deep sense of commitment, and his tireless efforts to elevate every student-driven initiative are truly inspiring. Every time I see that fire in his eyes, I am reminded that true leadership is about enabling others to rise. At AdametNext, we take immense pride in being the title sponsor of Samprabhav since its inception. Giving back to our alma mater is not just a responsibility; it’s a privilege. Supporting this event means nurturing the next generation of pharma leaders, ensuring that the legacy of NIPER MBA continues to thrive. Samprabhav is not just an event; it’s a celebration of passion, perseverance, and purpose. And as it continues to raise the bar year after year, we at AdametNext stand committed to fueling this journey, to honoring the vision of those who started it, and to empowering those who will take it forward. Here’s to the legacy, the leaders, and the limitless possibilities ahead! #Samprabhav2025 #NIPERMBA #LegacyOfExcellence #Adametnext #GivingBack NIPER S.A.S. NAGAR Training and Placement Cell NIPER Placement Cell National Institute of Pharmaceutical Education and Research (NIPER) ,SAS NAGAR , Mohali Department of Pharmaceutical Management, NIPER S.A.S. Nagar (Mohali)

𝐋𝐚𝐭𝐞𝐬𝐭 𝐄𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 We are excited to present the latest edition of our newsletter, providing business -critical events in the respiratory portfolio. This edition focuses on key areas such as 𝐀𝐬𝐭𝐡𝐦𝐚, 𝐂𝐎𝐏𝐃, 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐂𝐨𝐮𝐠𝐡, 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐇𝐲𝐩𝐞𝐫𝐭𝐞𝐧𝐬𝐢𝐨𝐧, 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬, 𝐚𝐧𝐝 𝐂𝐲𝐬𝐭𝐢𝐜 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬. For a quick overview, check out the Executive Summary, which highlights the most important updates at a glance. This edition includes recent updates from companies, including Sanofi, Merck Life Science, Vicore Pharma AB, Nuance Pharma, HARBOUR BIOMED, Kinaset Therapeutics and others. Dive deeper into the respiratory and pulmonary landscape with in-depth coverage, including: ✅ Investor Presentation Benchmark Analysis: We also have performed a comprehensive assessment of key companies in the respiratory portfolio, analysing their investor presentations in detail ✅ Market landscape analysis ✅ Company competitive analysis ✅ Strategy and market opportunities ✅ Key Upcoming Milestones: Major data readouts and approval timeline estimates Looking for tailored insights or support for your strategic initiatives? Reach out to us at [email protected] 𝐏𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐛𝐲: Ziya Pailwan, Mritunjay Singh Chandel Virendra Kumar AdametNext  AstraZeneca, Tectonic Therapeutic, Inc., United Therapeutics Corporation, Enveda, Krystal Biotech, Inc., Gossamer Bio, Protalix Biotherapeutics #RespiratoryPortfolio #MarketInsights #Respiratory #Competitiveintelligence #Strategyandinsights #Adametnext

𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐈𝐠𝐀 𝐍𝐞𝐩𝐡𝐫𝐨𝐩𝐚𝐭𝐡𝐲: 𝐊𝐞𝐲 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 & 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬   𝐈𝐠𝐀 𝐍𝐞𝐩𝐡𝐫𝐨𝐩𝐚𝐭𝐡𝐲 (𝐈𝐠𝐀𝐍), 𝐨𝐫 𝐁𝐞𝐫𝐠𝐞𝐫'𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞, is a complex kidney disorder marked by IgA deposits in the glomeruli, leading to inflammation and potential progression to end-stage renal disease (ESRD). While RAAS blockers and blood pressure control remain the cornerstone of treatment, the risk of kidney failure persists, highlighting the critical need for novel therapies.   🚀 𝐖𝐡𝐚𝐭'𝐬 𝐂𝐡𝐚𝐧𝐠𝐢𝐧𝐠? 🔹𝐒𝐩𝐚𝐫𝐬𝐞𝐧𝐭𝐚𝐧 – Recently approved to reduce proteinuria burden 🔹𝐒𝐆𝐋𝐓𝟐 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 – Gaining traction for slowing disease progression 🔹𝐀𝐭𝐫𝐚𝐬𝐞𝐧𝐭𝐚𝐧 (𝐀𝐒𝐒𝐈𝐒𝐓 𝐏𝐡𝟐 𝐭𝐫𝐢𝐚𝐥) – A promising candidate in ongoing trials   🏥 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Arrowhead Pharmaceuticals, Takeda, Apellis Pharmaceuticals, Biogen, Novartis, RemeGen Biosciences, Vera Therapeutics, Inc., Roche, Otsuka Pharmaceutical Companies (U.S.), Travere Therapeutics, Calliditas Therapeutics, Vertex Pharmaceuticals   With 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐥𝐚𝐭𝐞-𝐬𝐭𝐚𝐠𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 in progress, the future of IgAN treatment is evolving towards 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐚𝐧𝐝 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐢𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐬. Prepared by Amit Arya, PhD, Vertika Jain, Simrat Kaur, Kalyani Jungare, and Arpita Panigrahi Reach out to us at [email protected] for more insights! Virendra Kumar AdametNext   #IgAN #IgANephropathy #KidneyDisease #Nephrology #Strategy #MarketIntelligence #CompetitiveIntelligence #Adametnext

Understanding the Growth, Demand and Competitive Landscape of Travel Vaccines Our in-depth report covers 𝐌𝐚𝐫𝐤𝐞𝐭 𝐨𝐯𝐞𝐫𝐯𝐢𝐞𝐰, 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐚𝐧𝐝 𝐂𝐃𝐂 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 for travel vaccines. Stay informed and ahead in this evolving space—check out the report now  For more updates, please write us at [email protected] Virendra Kumar Amit Pharande AdametNext #Travelvaccines #Competitiveintelligence #Adametnext

🚀 Empowering Market Access with Precision & Innovation! 💡 A well-crafted Budget Impact Model (BIM) is more than just numbers—it’s a strategic tool that empowers payers and market access leaders to make informed reimbursement decisions, optimize resource allocation, and demonstrate the true value of innovation. That's why at AdametNext, we build flexible, transparent, and tailored health economic models that resonate with payers, HTA bodies, and market access leaders. ✨ Our Cross-Indication BIM Capabilities Include: 🔹 Holistic & Flexible Approach – Supports multiple indications & time horizons 🔹 PICO-Structured Framework – Ensuring clinical relevance & transparency 🔹 Scenario Analysis & Market Share Estimations – Practical insights for decision-makers 🔹 ISPOR-Compliant & Best Practices Aligned – Trusted by global stakeholders 🔹 Client-Centric & Adaptive – Rapid adaptation for country-level needs 🔹 Auto-PPT Generation & User-Friendly Guide – Seamless adoption & presentation 📌 Success in Action: Our multi-indication BIM for a major treatment launch was exceptionally well-received, leading to rapid adoption by country teams! 🌍 💬 Are you looking to enhance your market access strategy with a robust BIM? Let’s connect! 📩 📧 Contact us: 📨 [email protected] | [email protected] 📞 US: +1 (470) 886 7634 #AdametNext #BudgetImpactModel #MarketAccess #HEOR #Pharma #EconomicModelling #HealthEconomics #HTA #Reimbursement #PharmaceuticalIndustry #GlobalMarketAccess #USHealthcare #EUHealthcare #ISPOR

𝐒𝐀𝐌𝐏𝐑𝐀𝐁𝐇𝐀𝐕 𝟐𝟎𝟐𝟓 - 𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐝𝐚𝐦𝐞𝐭𝐍𝐞𝐱𝐭! Great events are built on great collaborations, and we are proud to have AdametNext as our 𝐓𝐢𝐭𝐥𝐞 𝐒𝐩𝐨𝐧𝐬𝐨𝐫. With a powerhouse team of pharma strategists, they don’t just provide insights, they transform data into decisions that shape the industry. From brand strategy to real-time market intelligence, AdametNext ensures businesses stay ahead with expert-driven solutions and a 360-degree approach to brand success. Their commitment to empowering pharma with actionable, game-changing insights makes them the perfect partner for SAMPRABHAV 2025. Here’s to a collaboration that fuels knowledge, strengthens strategies, and drives the future of healthcare! #samprabhav #samprabhav2025 #dopm #niper #pharmaceutical #management #adametnext

𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐎𝐮𝐫 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 We are thrilled to announce the release of our latest newsletter, covering business-critical events in the respiratory portfolio. This edition focuses on key areas such as 𝐀𝐬𝐭𝐡𝐦𝐚, 𝐂𝐎𝐏𝐃, 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐂𝐨𝐮𝐠𝐡, 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐇𝐲𝐩𝐞𝐫𝐭𝐞𝐧𝐬𝐢𝐨𝐧, 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬, 𝐚𝐧𝐝 𝐂𝐲𝐬𝐭𝐢𝐜 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬.   For a quick overview, check out the Executive Summary, which highlights the most important updates at a glance. This edition has recent updates from companies, including AstraZeneca, Vertex Pharmaceuticals, ALIVEGEN USA, INC., Windward Bio, tiakis Biotech AG, MediaRadar, Inc. and Lupin.   Dive deeper into the respiratory and pulmonary landscape with in-depth coverage, including: ✅ Market landscape analysis ✅ Company competitive analysis ✅ Strategy and market opportunities ✅ Key upcoming milestones   Looking for tailored insights or support for your strategic initiatives? Reach out to us at [email protected]. 𝐏𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐛𝐲: Ziya Pailwan, Mritunjay Singh Chandel Virendra Kumar AdametNext #RespiratoryPortfolio #MarketInsights #Respiratory #Competitiveintelligence #Strategyandinsights United Therapeutics Corporation, VICORE HEALTH LTD, Krystal Biotech, Inc. and Protalix Biotherapeutics.

Welcome to AdametNext, Ghanendra Kumar! We are thrilled to announce that Ghanendra kumar has joined our team at AdametNext! With a wealth of experience and a passion for innovation, Ghanendra is set to make a significant impact on our projects and initiatives. Let's give Ghanendra, a warm welcome and show our support as they embark on this exciting journey with us. #AdametNext

Happy 76th Republic Day! On this momentous day, we at AdametNext join the nation in celebrating 76 years of our Republic—a journey shaped by the values of democracy, equality, and progress. This day reminds us of the strength and resilience of our Constitution, which continues to guide our path toward a brighter and more inclusive future. Let’s take this opportunity to reflect on our shared responsibility as citizens and professionals to contribute to India’s growth and uphold the principles that make our nation great. Wishing everyone a day filled with pride, unity, and celebration! Together, let’s keep building a stronger, more innovative, and inclusive India. Jai Hind! #76thRepublicDay #ProudIndian #TeamAdametNext #UnityInDiversity AdametNext